Orphazyme after FDA meeting: New phase II/III trial won't be necessary

No new phase II/III study is required pertaining to a potential US approval of the lead cnadidate arimoclomol, which is meant to treat Niemann-Pick disease type C, Chief Financial Officer at Orphazyme Anders Vadsholt tells MedWatch.

Photo: Orphazyme / PR

It appears that Orphazyme will steer clear of the worst case scenario on the path toward US approval with its lead candidate arimoclomol, a treatment for the neurodegenerative disease, Niemann-Pick disease type C (NPC).

Chief Financial Officer at Orphazyme Anders Vadsholt tells Medwatch that the US Food and Drug Administration (FDA) has returned to the company with no additional requirement for a new and costly phase II/III trial before the drug's resubmission. This comes after a June meeting between the FDA and the Copenhagen-based biotech company regarding the FDA's rejection of arimoclomol this summer.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs